Alkermes Advances ALKS 2680 Into Phase 3 for Narcolepsy Type 1: What Investors Should Watch

Alkermes plc (ALKS) announced an update on their ongoing clinical study.

The Brilliance NT1 Study 302 is a Phase 3 trial run by Alkermes, Inc. to test ALKS 2680 in adults with narcolepsy type 1. It aims to see if the drug can cut daytime sleepiness, reduce cataplexy attacks, and ease core disease symptoms compared with placebo, a key step before any filing or launch.

ALKS 2680, also called Alixorexton, is an oral tablet given once daily for 12 weeks. The study compares two dose levels of ALKS 2680 against matching placebo tablets to pinpoint a dose that balances symptom control with safety.

The study is interventional and randomized, meaning participants are assigned by chance to drug or placebo groups. It is double blind in practice, with patients, care teams, and investigators unaware of who gets what, and its main goal is to test treatment benefit rather than just observe disease.

The trial status is “not yet recruiting,” with the study first submitted on 3 Mar 2026 and last updated the same day, signaling a fresh launch. Primary completion and final completion dates are not yet posted, so investors should assume data readouts are several years away, fitting a standard late-stage timeline.

For investors, this update moves ALKS 2680 into pivotal testing in a focused sleep-disorder niche often served by companies like Jazz Pharma and others in rare neurologic conditions. A successful Phase 3 could open a new growth stream for Alkermes and lift sentiment, while any delay or safety concern could weigh on shares in a crowded, competitive space.

The Brilliance NT1 Study 302 is now an active, planned Phase 3 effort, with further details and ongoing updates available on the ClinicalTrials.gov portal.

To learn more about ALKS’s potential, visit the Alkermes plc drug pipeline page.